Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study
Open Access
- 26 March 2024
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 95 (6) , 1099-1111
Abstract
Objective: Although off‐label use of rituximab is a common alternative to disease‐modifying therapies (DMTs) approved for multiple sclerosis (MS) in several countries, the impact of this on treatment cost‐effectiveness is not well known.Methods: We evaluated the relative cost‐effectiveness of rituximab and MS‐approved DMTs in a register‐based cohort study of Swedish residents with relapsing–remitting MS, aged 18–65 years, starting treatment with rituximab, natalizumab, fingolimod, or dimethyl fumarate between January 2010 and July 2016, and followed through July 2021 (n = 5,924). By linking the population‐based Swedish MS register to several Swedish health care and demographic registers, we estimated health care costs in relation to number of relapses, over 5 years from treatment start. Differences between treatments were estimated in inverse probability of treatment‐weighted regression models, adjusting for a broad range of potential confounders covering demographics, medical history, and MS‐related clinical characteristics.Results: Off‐label rituximab was associated with both lower total health care costs (mean cost savings ranged $35,000–$66,000 vs. each approved DMT), and fewer relapses (mean number of prevented relapses ranged 0.12–0.22), per started therapy over 5 years. Results were robust to variations in discounting and pricing of health care visits, with the main driver of cost‐savings being the price of the index drug itself.Interpretation: The cost‐effectiveness of rituximab dominated the MS‐approved alternatives. Off‐label, low‐dose rituximab should be considered for persons with MS and could reduce barriers to treatment, especially in resource‐limited settings. ANN NEUROL 2024;95:1099–1111Keywords
Funding Information
- Vetenskapsrådet (2020‐02700, 2021‐01968)
- Neuroförbundet
This publication has 35 references indexed in Scilit:
- Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple SclerosisJAMA Neurology, 2024
- Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System LevelAnnals of Neurology, 2022
- Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosisJournal of Neurology, 2021
- Economics of Multiple Sclerosis Disease-Modifying Therapies in the USACurrent Neurology and Neuroscience Reports, 2021
- Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis PatientsAnnals of Neurology, 2020
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Combining multiple imputation and bootstrap in the analysis of cost‐effectiveness trial dataStatistics in Medicine, 2018
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple SclerosisJAMA Neurology, 2018
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patientsAnnals of Neurology, 2016
- A tutorial on propensity score estimation for multiple treatments using generalized boosted modelsStatistics in Medicine, 2013